This morning Elan and its partner Biogen announced that they have submitted a Biologics License Application to the US Food and Drug Administration for the approval of Antegren as a treatment for multiple sclerosis.
The submission includes one year data from two ongoing Phase 3 trials. In a statement, Elan said the two companies are committed to completing these two year trials.
'This submission represents a significant milestone for Elan and Biogen and demonstrates our continued commitment to providing a new treatment option for the more than one million patients experiencing the debilitating effects of MS,' said Lars Ekman, Executive Vice President and President of Elan's Research and Development.
Elan shares gained 8 cent to stand at €18.05 in Dublin this afternoon.
